Nobel Biocare sues
Two subsidiaries of
The NobelActive® line has grown to become one of the world's most popular dental implants, supported by Nobel Biocare's commitment to Research & Development (R&D) spending, extensive clinical studies, and training programs for clinicians. Both US patents asserted in the lawsuit relate to technology for aiding the surgical installation and successful integration of the implants in a variety of patient bone types. Nobel Biocare asks the court for an injunction barring sales of Neodent's infringing dental implants, payment of money damages due to Nobel Biocare's lost sales, and to recover its attorney fees for the lawsuit.
Investor & Corporate Relations
Tel: +41 43 211 42 30, +41 79 430 81 46
Nobel Biocare (NOBN,
This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.
Media Release (PDF)
|Provider/Channel related enquiries|
+41 41 763 00 50